Publication details

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Authors

SVATON Martin ZEMANOVA Milada ZEMANOVA Petra KULTAN Juraj FISCHER Ondrej SKŘIČKOVÁ Jana JAKUBÍKOVÁ Lenka CERNOVSKA Marketa HRNCIARIK Michal JIROUSEK Michal KREJCI Jana KREJCI Daniel BÍLEK Ondřej BLAZEK Jiri HURDÁLKOVÁ Karolína BAŘINOVÁ Magda MELICHAR Bohuslav

Year of publication 2020
Type Article in Periodical
Magazine / Source Anticancer Research
MU Faculty or unit

Faculty of Medicine

Citation
Web http://ar.iiarjournals.org/content/40/4/2209.abstract
Doi http://dx.doi.org/10.21873/anticanres.14182
Keywords Nivolumab; non-small cell lung cancer; corticoids; antibiotics; proton pump inhibitors; NSAID; statins; metformin
Description Aim: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Results: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. Conclusion: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.

You are running an old browser version. We recommend updating your browser to its latest version.

More info